Ravulizumab for COVID-19

Official Title

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

Study Details

This study intends to evaluate the safety and efficacy of ravulizumab for the treatment of COVID-19 severe pneumonia, acute lung injury or acute respiratory distress syndrome (ARDS).

Principal Investigator

Dr. Hrishikesh Kulkarni

IRB Number



1. Participants must be 18 or older and admitted to Barnes Jewish Hospital
2. Participants must have have either severe pneumonia, Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) associated with a confirmed COVID 19 infection (caused by a virus called Severe Acute Respiratory Syndrome-CoronaVirus 2 or SARS CoV 2)

Volunteer Information

For more information about this study, contact Volunteer for Health at: